Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT00517361
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • carboplatin — DRUG
    AUC 6 in 250mL saline IV over 30 minutes
  • bevacizumab — DRUG
    15mg/kg in 100mL saline IV over 60 - 90 minutes

Study Details

The purpose of this study is to determine the progression free survival (PFS) of metastatic ER, PR and HER2/neu negative breast cancers to the combination of carboplatin and bevacizumab (Avastin®) therapy.

Key Dates

First listed
Aug 16, 2007
Start date
Aug 31, 2007
Status verified
Mar 2014
Primary completion
Apr 30, 2011
Completion
Apr 30, 2012

Study Design

Enrollment
11 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Carboplatin + Avastin

Primary Outcome Measure

Progression Free Survival [ Time Frame: Up to 5 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of ChicagoChicagoIllinois60637-
Oncology SpecialistsPark RidgeIllinois60068-

Find similar trials in Chicago, IL

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
University of Chicago· Chicago, ILOncology Specialists· Park Ridge, IL

Related Studies